• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • B. Ya. Ettinger, Dennis M Black, +15 authors Steven R Cummings
  • Medicine
  • JAMA
  • 1999 (First Publication: 18 August 1999)
  • CONTEXT Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known. OBJECTIVE ToContinue Reading
  • Charles H. Chesnut, Arne Skag, +8 authors Pierre Delmas
  • Medicine
  • Journal of bone and mineral research : the…
  • 2004 (First Publication: 1 August 2004)
  • UNLABELLED Oral daily (2.5 mg) and intermittent ibandronate (between-dose interval of >2 months), delivering a similar cumulative exposure, were evaluated in 2946 osteoporotic women with prevalentContinue Reading
  • Pierre Delmas, Silvano Adami, +13 authors David M. Reid
  • Medicine
  • Arthritis and rheumatism
  • 2006 (First Publication: 1 June 2006)
  • OBJECTIVE Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administeredContinue Reading
  • Pierre Delmas, Robert R. Recker, +7 authors For the Oral Ibandronate Osteoporosis Vertebral Fractu Europe
  • Medicine
  • Osteoporosis International
  • 2004 (First Publication: 1 October 2004)
  • Increasing evidence suggests that a high rate of bone turnover is associated with low bone mineral density (BMD) and is strongly linked to fracture risk. Measurement of biochemical markers of boneContinue Reading
  • Jacob A. Stakkestad, Peter Lakatos, Roman Lorenc, Farhad Sedarati, Colin Neate, J. Reginster
  • Medicine
  • Clinical Rheumatology
  • 2007 (First Publication: 1 August 2008)
  • AbstractOral ibandronate is the first bisphosphonate licensed for once-monthly treatment of postmenopausal osteoporosis. The 2-year Monthly Oral iBandronate In LadiEs (MOBILE) registration studyContinue Reading